F m Investments LLC Acquires 8,627 Shares of TransMedics Group, Inc. $TMDX

F m Investments LLC raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 15.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,539 shares of the company’s stock after purchasing an additional 8,627 shares during the period. F m Investments LLC owned 0.19% of TransMedics Group worth $7,973,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of TMDX. Whittier Trust Co. of Nevada Inc. raised its position in TransMedics Group by 981.0% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new position in TransMedics Group during the 3rd quarter valued at approximately $29,000. Optiver Holding B.V. raised its position in TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after purchasing an additional 191 shares during the last quarter. Allworth Financial LP raised its position in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the last quarter. Finally, LOM Asset Management Ltd bought a new position in TransMedics Group during the 3rd quarter valued at approximately $34,000. Institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on TMDX. Piper Sandler lowered their price target on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday. TD Cowen lowered their price target on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a research report on Wednesday. Oppenheimer downgraded TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday. Stifel Nicolaus reduced their target price on TransMedics Group from $130.00 to $85.00 and set a “hold” rating on the stock in a report on Wednesday. Finally, JPMorgan Chase & Co. upped their target price on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $135.00.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director David Weill sold 3,571 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $146.82, for a total transaction of $524,294.22. Following the completion of the sale, the director directly owned 12,134 shares in the company, valued at approximately $1,781,513.88. This trade represents a 22.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Nicholas Corcoran sold 2,966 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $412,629.92. Following the sale, the insider owned 29,831 shares of the company’s stock, valued at approximately $4,150,088.72. This represents a 9.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 16,205 shares of company stock worth $2,353,002 in the last 90 days. Insiders own 6.90% of the company’s stock.

TransMedics Group Stock Performance

TransMedics Group stock opened at $68.00 on Friday. The company has a quick ratio of 6.59, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The company has a market capitalization of $2.35 billion, a P/E ratio of 15.45 and a beta of 2.07. The stock’s 50 day moving average is $114.04 and its 200 day moving average is $125.34. TransMedics Group, Inc. has a twelve month low of $67.69 and a twelve month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The firm had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.70 earnings per share. On average, equities research analysts predict that TransMedics Group, Inc. will post 2.22 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.